WASHINGTON, D.C.—U.S. Chamber of Commerce Executive Vice President and Chief Policy Officer Neil Bradley issued the following statement in response to President Trump’s letters to various life science company CEOs regarding the implementation of Most Favored Nation (MFN) reference pricing:
"Importing foreign price controls into the U.S. healthcare system will harm patients by delaying access to new, life-saving medicines. The Chamber’s research reveals that in countries with price controls, patients face significantly reduced access to new treatments, with delays of up to 500 days in some cases. Additionally, our research highlights that such policies could lead to a 75% decline in U.S. clinical trial activity, jeopardizing innovation in critical areas like cancer, obesity, and rare and chronic diseases. We urge the administration to reject these harmful policies and instead focus on market-driven solutions that preserve innovation and ensure timely access to breakthrough treatments for American patients."
###
